Wen Xue

List of Publications by Citations

48 papers	6,400 citations	27 h-index	57 g-index
57 ext. papers	7,730 ext. citations	20.4 avg, IF	5.51 L-index

#	Paper	IF	Citations
48	Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature*, **2007**, 445, 656-60	50.4	1786
47	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nature Biotechnology*, **2014**, 32, 551-3	44.5	694
46	Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. *Nature Biotechnology*, **2016**, 34, 328-33	44.5	610
45	CRISPR-mediated direct mutation of cancer genes in the mouse liver. *Nature*, **2014**, 514, 380-4	50.4	521
44	KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell*, **2014**, 158, 171-84	56.2	482
43	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. *Nature*, **2014**, 516, 428-31	50.4	278
42	Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. *Nature Biotechnology*, **2017**, 35, 1179-1187	44.5	255
41	Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. *Human Gene Therapy*, **2015**, 26, 432-42	4.8	226
40	Small RNA combination therapy for lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E3553-61	11.5	177
39	Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. *Nature Chemical Biology*, **2018**, 14, 311-316	11.7	140
38	Response and resistance to NF-B inhibitors in mouse models of lung adenocarcinoma. *Cancer Discovery*, **2011**, 1, 236-47	24.4	104
37	CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. *Genome Biology*, **2017**, 18, 108	18.3	103
36	Adenine base editing in an adult mouse model of tyrosinaemia. *Nature Biomedical Engineering*, **2020**, 4, 125-130	19	86
35	A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing. *Molecular Cell* , **2019**, 73, 714-726.e4	17.6	85
34	CRISPR-Cas: a tool for cancer research and therapeutics. *Nature Reviews Clinical Oncology*, **2019**, 16, 281-295	19.4	83
33	Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma. *Cancer Cell*, **2017**, 32, 101-114.e8	24.3	83
32	Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. *Gastroenterology*, **2017**, 152, 1161-1173.e1	13.3	63

31	Precision cancer mouse models through genome editing with CRISPR-Cas9. *Genome Medicine*, **2015**, 7, 53	14.4	61
30	All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. *Genome Biology*, **2018**, 19, 137	18.3	58
29	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. *Genome Biology*, **2015**, 16, 111	18.3	45
28	Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. *Nature Communications*, **2021**, 12, 2121	17.4	45
27	In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. *Human Gene Therapy*, **2018**, 29, 853-860	4.8	40
26	Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases. *Theranostics*, **2020**, 10, 4374-4382	12.1	38
25	Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins. *Rna*, **2019**, 25, 1421-1431	5.8	35
24	A Modular Assembly Platform for Rapid Generation of DNA Constructs. *Scientific Reports*, **2016**, 6, 16836	4.9	34
23	Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. *Nature Communications*, **2020**, 11, 1979	17.4	31
22	Targeted Metabolomics Identifies the Cytochrome P450 Monooxygenase Eicosanoid Pathway as a Novel Therapeutic Target of Colon Tumorigenesis. *Cancer Research*, **2019**, 79, 1822-1830	10.1	29
21	Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3648-3653	11.5	24
20	Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. *Hepatology*, **2020**, 71, 275-290	11.2	24
19	Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. *Nature Biotechnology*, **2018**, 36, 839-842	44.5	23
18	Comprehensive identification of alternative back-splicing in human tissue transcriptomes. *Nucleic Acids Research*, **2020**, 48, 1779-1789	20.1	22
17	The NIH Somatic Cell Genome Editing program. *Nature*, **2021**, 592, 195-204	50.4	21
16	Deletion and replacement of long genomic sequences using prime editing. *Nature Biotechnology*, **2021**,	44.5	13
15	RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. *Journal of Hepatology*, **2016**, 64, 899-907	13.4	9
14	The temporal landscape of recursive splicing during Pol II transcription elongation in human cells. *PLoS Genetics*, **2018**, 14, e1007579	6	9

13	CRISPR-Cas-related technologies in basic and translational liver research. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 251-252	24.2	8
12	Genomic Amplifications Cause False Positives in CRISPR Screens. *Cancer Discovery*, **2016**, 6, 824-6	24.4	8
11	YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells. *Hepatology*, **2021**, 73, 1011-1027	11.2	6
10	Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. *Nature Communications*, **2021**, 12, 6267	17.4	5
9	Understanding and repurposing CRISPR-mediated alternative splicing. *Genome Biology*, **2018**, 19, 184	18.3	5
8	CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. *Genome Medicine*, **2019**, 11, 21	14.4	4
7	Real-time imaging of integrin 4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing. *Journal of Cell Science*, **2019**, 132,	5.3	4
6	Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. *Hepatology*, **2021**, 74, 233-247	11.2	3
5	A flexible split prime editor using truncated reverse transcriptase improves dual AAV delivery in mouse liver.. *Molecular Therapy*, **2022**,	11.7	2
4	Genome-wide detection of CRISPR editing in vivo using GUIDE-tag.. *Nature Communications*, **2022**, 13, 437	17.4	1
3	Tissue-specific Genome Editing in vivo by MicroRNA-repressible Anti-CRISPR Proteins		1
2	Programming large target genomic deletion and concurrent insertion via a prime editing-based method: PEDAR		1
1	Leveraging the Treg-intrinsic CTLA4-PKC signaling pathway for cancer immunotherapy **2021**, 9,		1